165 related articles for article (PubMed ID: 8416597)
1. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YF; Jann MW
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):105-12. PubMed ID: 8416597
[TBL] [Abstract][Full Text] [Related]
2. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
[TBL] [Abstract][Full Text] [Related]
3. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
Viala A; Aymard N; Leyris A; Caroli F
Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
[TBL] [Abstract][Full Text] [Related]
4. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
Chang WH; Lin SK; Jann MW
J Clin Psychopharmacol; 1991 Apr; 11(2):99-105. PubMed ID: 2056148
[TBL] [Abstract][Full Text] [Related]
5. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia.
Stevens A; Mahal A; Gaertner HJ
Pharmacopsychiatry; 1992 Sep; 25(5):218-23. PubMed ID: 1409866
[TBL] [Abstract][Full Text] [Related]
6. Haloperidol decanoate pharmacokinetics in red blood cells and plasma.
Dysken MW; Kim SW; Vatassery G; Johnson SB; Skare S; Holden L; Thomsyck L
J Clin Psychopharmacol; 1992 Apr; 12(2):128-32. PubMed ID: 1573034
[TBL] [Abstract][Full Text] [Related]
7. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence.
Vasavan Nair NP; Suranyi-Cadotte B; Schwartz G; Thavundayil JX; Achim A; Lizondo E; Nayak R
J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):30S-37S. PubMed ID: 3514689
[TBL] [Abstract][Full Text] [Related]
9. The response of untreated chronic schizophrenics to haloperidol and haloperidol decanoate.
Leff JP; Tress KH
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():27-40. PubMed ID: 3559160
[TBL] [Abstract][Full Text] [Related]
10. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate.
Gelders YG
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-11. PubMed ID: 3559159
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic of haloperidol decanoate in psychotic patients (author's transl)].
Parent M; Toussaint C; Driesens F; Gelders Y
Acta Psychiatr Belg; 1981; 81(4):399-406. PubMed ID: 7331843
[No Abstract] [Full Text] [Related]
13. 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate.
Sassa T; Suhara T; Ikehira H; Obata T; Girard F; Tanada S; Okubo Y
Psychiatry Clin Neurosci; 2002 Dec; 56(6):637-42. PubMed ID: 12485307
[TBL] [Abstract][Full Text] [Related]
14. Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate.
Jann MW; Wei FC; Lin HN; Piao-Chien C; Chang WH
Prog Neuropsychopharmacol Biol Psychiatry; 1996 Jan; 20(1):73-86. PubMed ID: 8861178
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia.
Meco G; Falaschi P; Casacchia M; Rocco A; Petrini P; Rosa M; Agnoli A
Adv Biochem Psychopharmacol; 1985; 40():89-93. PubMed ID: 4025041
[No Abstract] [Full Text] [Related]
16. Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison.
Eberhard G; Hellbom E
Acta Psychiatr Scand; 1986 Sep; 74(3):255-62. PubMed ID: 3788652
[TBL] [Abstract][Full Text] [Related]
17. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients.
Nayak RK; Doose DR; Nair NP
J Clin Pharmacol; 1987 Feb; 27(2):144-50. PubMed ID: 3680566
[TBL] [Abstract][Full Text] [Related]
18. Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction.
Someya T; Shibasaki M; Noguchi T; Takahashi S; Inaba T
J Clin Psychopharmacol; 1992 Jun; 12(3):169-74. PubMed ID: 1629382
[TBL] [Abstract][Full Text] [Related]
19. Haloperidol decanoate (Janssen) in the treatment of schizophrenia.
Zbytovský J
Cesk Psychiatr; 1993 Jan; 89(1):27-9. PubMed ID: 8099537
[TBL] [Abstract][Full Text] [Related]
20. Haloperidol decanoate.
Nasser J; Thomas B
Aust N Z J Psychiatry; 1989 Sep; 23(3):311-2. PubMed ID: 2803140
[No Abstract] [Full Text] [Related]
[Next] [New Search]
